Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19

Autores
Magaña, Angel J.; Ngo, David; Faccone, Diego Francisco; Gómez, Sonia Alejandra; Corso, Alejandra; Pasteran, Fernando; Ramirez, María Soledad; Tolmasky, Marcelo E.
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The most common clinical manifestations of Klebsiella pneumoniae infectionare pneumonia, septicemias, meningitis, and urinary tract or soft tissue infections[1]. Besides being a major cause of neonatal and adult sepsis, K. pneumoniae isalso associated with other diseases like ankylosing spondylitis, liver abscess,and Crohn's disease [1]. The emergence of carbapenem-resistant K.pneumoniae (CRKP) strains has substantially increased morbidity and mortalitydue to infections caused by this bacterium, warranting its placement at the top ofthe World Health Organization's priority list [2]. CRKP-associated mortality ratesin nosocomial infections are as high as 50% [3]. Furthermore, CRKP is within thelist of bacterial pathogens that increased antimicrobial-resistant hospital-onsetinfections by 20% during the COVID-19 pandemic [4].
Fil: Magaña, Angel J.. California State University; Estados Unidos
Fil: Ngo, David. California State University; Estados Unidos
Fil: Faccone, Diego Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Gómez, Sonia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Corso, Alejandra. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Pasteran, Fernando. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Ramirez, María Soledad. California State University; Estados Unidos
Fil: Tolmasky, Marcelo E.. California State University; Estados Unidos
Materia
KLEBSIELLA PNEUMONIAE
AMIKACIN
CARBAPENEM
COVID-19
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/250748
Acceder
id CONICETDig_6fcf38274cf537ba268732bf7d36393d
oai_identifier_str oai:ri.conicet.gov.ar:11336/250748
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19Magaña, Angel J.Ngo, DavidFaccone, Diego FranciscoGómez, Sonia AlejandraCorso, AlejandraPasteran, FernandoRamirez, María SoledadTolmasky, Marcelo E.KLEBSIELLA PNEUMONIAEAMIKACINCARBAPENEMCOVID-19https://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The most common clinical manifestations of Klebsiella pneumoniae infectionare pneumonia, septicemias, meningitis, and urinary tract or soft tissue infections[1]. Besides being a major cause of neonatal and adult sepsis, K. pneumoniae isalso associated with other diseases like ankylosing spondylitis, liver abscess,and Crohn's disease [1]. The emergence of carbapenem-resistant K.pneumoniae (CRKP) strains has substantially increased morbidity and mortalitydue to infections caused by this bacterium, warranting its placement at the top ofthe World Health Organization's priority list [2]. CRKP-associated mortality ratesin nosocomial infections are as high as 50% [3]. Furthermore, CRKP is within thelist of bacterial pathogens that increased antimicrobial-resistant hospital-onsetinfections by 20% during the COVID-19 pandemic [4].Fil: Magaña, Angel J.. California State University; Estados UnidosFil: Ngo, David. California State University; Estados UnidosFil: Faccone, Diego Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; ArgentinaFil: Gómez, Sonia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; ArgentinaFil: Corso, Alejandra. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; ArgentinaFil: Pasteran, Fernando. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; ArgentinaFil: Ramirez, María Soledad. California State University; Estados UnidosFil: Tolmasky, Marcelo E.. California State University; Estados UnidosElsevier2024-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/250748Magaña, Angel J.; Ngo, David; Faccone, Diego Francisco; Gómez, Sonia Alejandra; Corso, Alejandra; et al.; Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19; Elsevier; Journal of Global Antimicrobial Resistance; 40; 11-2024; 8-102213-7165CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2213716524004478info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jgar.2024.11.007info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:55:08Zoai:ri.conicet.gov.ar:11336/250748instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:55:09.03CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
title Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
spellingShingle Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
Magaña, Angel J.
KLEBSIELLA PNEUMONIAE
AMIKACIN
CARBAPENEM
COVID-19
title_short Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
title_full Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
title_fullStr Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
title_full_unstemmed Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
title_sort Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19
dc.creator.none.fl_str_mv Magaña, Angel J.
Ngo, David
Faccone, Diego Francisco
Gómez, Sonia Alejandra
Corso, Alejandra
Pasteran, Fernando
Ramirez, María Soledad
Tolmasky, Marcelo E.
author Magaña, Angel J.
author_facet Magaña, Angel J.
Ngo, David
Faccone, Diego Francisco
Gómez, Sonia Alejandra
Corso, Alejandra
Pasteran, Fernando
Ramirez, María Soledad
Tolmasky, Marcelo E.
author_role author
author2 Ngo, David
Faccone, Diego Francisco
Gómez, Sonia Alejandra
Corso, Alejandra
Pasteran, Fernando
Ramirez, María Soledad
Tolmasky, Marcelo E.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv KLEBSIELLA PNEUMONIAE
AMIKACIN
CARBAPENEM
COVID-19
topic KLEBSIELLA PNEUMONIAE
AMIKACIN
CARBAPENEM
COVID-19
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The most common clinical manifestations of Klebsiella pneumoniae infectionare pneumonia, septicemias, meningitis, and urinary tract or soft tissue infections[1]. Besides being a major cause of neonatal and adult sepsis, K. pneumoniae isalso associated with other diseases like ankylosing spondylitis, liver abscess,and Crohn's disease [1]. The emergence of carbapenem-resistant K.pneumoniae (CRKP) strains has substantially increased morbidity and mortalitydue to infections caused by this bacterium, warranting its placement at the top ofthe World Health Organization's priority list [2]. CRKP-associated mortality ratesin nosocomial infections are as high as 50% [3]. Furthermore, CRKP is within thelist of bacterial pathogens that increased antimicrobial-resistant hospital-onsetinfections by 20% during the COVID-19 pandemic [4].
Fil: Magaña, Angel J.. California State University; Estados Unidos
Fil: Ngo, David. California State University; Estados Unidos
Fil: Faccone, Diego Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Gómez, Sonia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Corso, Alejandra. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Pasteran, Fernando. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina
Fil: Ramirez, María Soledad. California State University; Estados Unidos
Fil: Tolmasky, Marcelo E.. California State University; Estados Unidos
description The most common clinical manifestations of Klebsiella pneumoniae infectionare pneumonia, septicemias, meningitis, and urinary tract or soft tissue infections[1]. Besides being a major cause of neonatal and adult sepsis, K. pneumoniae isalso associated with other diseases like ankylosing spondylitis, liver abscess,and Crohn's disease [1]. The emergence of carbapenem-resistant K.pneumoniae (CRKP) strains has substantially increased morbidity and mortalitydue to infections caused by this bacterium, warranting its placement at the top ofthe World Health Organization's priority list [2]. CRKP-associated mortality ratesin nosocomial infections are as high as 50% [3]. Furthermore, CRKP is within thelist of bacterial pathogens that increased antimicrobial-resistant hospital-onsetinfections by 20% during the COVID-19 pandemic [4].
publishDate 2024
dc.date.none.fl_str_mv 2024-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/250748
Magaña, Angel J.; Ngo, David; Faccone, Diego Francisco; Gómez, Sonia Alejandra; Corso, Alejandra; et al.; Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19; Elsevier; Journal of Global Antimicrobial Resistance; 40; 11-2024; 8-10
2213-7165
CONICET Digital
CONICET
url http://hdl.handle.net/11336/250748
identifier_str_mv Magaña, Angel J.; Ngo, David; Faccone, Diego Francisco; Gómez, Sonia Alejandra; Corso, Alejandra; et al.; Amikacin, in combination with cations, prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae strain isolated from a patient with COVID-19; Elsevier; Journal of Global Antimicrobial Resistance; 40; 11-2024; 8-10
2213-7165
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2213716524004478
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jgar.2024.11.007
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269327166799872
score 13.13397

Publicaciones similares